Business Wire

HSBC-HOLDINGS-PLC

19.10.2021 10:33:11 CEST | Business Wire | Press release

Share
New Research Shows Global Confidence Among Expats, as Nearly Two Thirds Feel Optimistic About the Next 12 Months

The 14th annual Expat Explorer study - a global survey of over 20,000 people who live and work abroad - indicates that almost two thirds (65%) of expats feel optimistic about the year ahead despite the volatility of the past 18 months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005540/en/

The key reason driving optimism is their hope to live ‘normally’ again (75%), but six in ten (61%) are also feeling positive because of the quality of life they will be able to enjoy. Expats in Taiwan are the most optimistic (85%), closely followed by those in Australia, New Zealand, and Vietnam (all 83%).

As the world has been in a state of flux during the pandemic, the study suggests that locations where a sense of stability has been maintained ranked highly. Nearly all expats based in Australia, Switzerland, and Jersey (in the Channel Islands) would recommend their location as a ‘stable’ place to live in the next 12 months - Australia (92%), Switzerland (92%), Jersey (90%).

Expats’ desire to live and work abroad has not been diminished by the pandemic – the majority plan to stay in their host location for the foreseeable future, with 80% intending to continue living in their host country for the next year at least, and only 7% planning to move.

The findings suggest expats are prioritising personal lifestyle choices rather than traditional relocation drivers - such as career progression (34%) or expanding professional network (31%). The top five goals that expats look forward to achieving in the next 12 months are:

  1. Getting to know the local area (50%)
  2. Travelling (47%)
  3. Understanding and exploring local culture (47%)
  4. Making new friends (45%)
  5. Going out more (41%)

Over two thirds (67%) of expats also believe their quality of life is better in their current location; those based in Indonesia and UAE feel the most fulfilled - 51% say they feel a stronger sense of fulfilment since moving there. Furthermore, globally, over two in five (46%) expats feel that their host communities have changed to be more supportive during the pandemic.

However, the study also highlights some of the challenges that expats have faced during the pandemic. Over half (63%) have been stopped from travelling abroad for business, and the majority (90%) were unable to see family or friends in their home countries. Yet it also points to the resilience of the global expat community, as two in five (42%) say they were able to continue to manage their physical health, and over a third (36%) continued to spend time outside.

Cameron Senior, Interim Head of HSBC Expat, said: "Despite incredibly challenging times, I am encouraged to see sparks of optimism among global expats. Our study confirms that expats continue to thrive in their host countries and many are looking forward to remaining there for the foreseeable future. Following many months of uncertainty, I’m heartened to hear how expats are benefitting from relocating – over two-thirds told us they feel their quality of life is better now, albeit with a lot of changes.

“Despite their positivity, I’m very mindful of the disruption they have experienced (which remains ongoing in certain locations) including their ability to see family or friends in their home countries, and travel for business. This reality puts their optimism in even sharper focus, and makes me more determined to fully support our expat customers as they navigate life away from home.

“So much has changed for global expats but I’m impressed by their resilience and optimism for the future. As the world begins to adjust, HSBC Expat is committed to opening up a world of opportunity for our customers who relocate overseas. We are dedicated to offering support to help them navigate and succeed in an increasingly globalised world.”

The study also shines light on expats’ financial lives, to gauge their financial goals in 2021. Three fifths (60%) wish to save for their retirement, almost a third are looking to build up an emergency savings fund (31%) and saving to purchase a property (30%). Over a fifth (23%) are saving or investing money for their children’s education.

Overall, expats ranked the following locations as the top 10 places to live and work in 2021:

  1. Switzerland
  2. Australia
  3. New Zealand
  4. UAE
  5. Guernsey
  6. Jersey
  7. Isle of Man
  8. Bahrain
  9. Singapore
  10. Qatar

For more information about the findings, and HSBC Expat products, visit: www.expat.hsbc.com/expat-explorer-results/

-Ends-

Notes to Editors

About Expat Explorer
Expat Explorer is a comprehensive and in-depth global survey of expats. The 2021 survey is HSBC’s broadest look at expat living to date, with expats from 46 countries and territories sharing their views. YouGov surveyed 20,460 adults aged 18+ currently living away from their country of origin/home country, in 143 countries, territories and markets, through an online questionnaire between March and May 2021. A minimum sample of 100 respondents was required for a location to qualify for inclusion; this year, 46 locations qualified.

HSBC Holdings plc
HSBC Holdings plc, the parent company of HSBC, is headquartered in London. HSBC serves customers worldwide from offices in 64 countries and territories in its geographical regions: Europe, Asia, North America, Latin America, and Middle East and North Africa. With assets of US$2,976bn at 30 June 2021, HSBC is one of the world’s largest banking and financial services organisations.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye